The 10-day RSI Indicator for BGMS moved out of overbought territory on September 16, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 instances where the indicator moved out of the overbought zone. In 22 of the 23 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The 10-day moving average for BGMS crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BGMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
BGMS broke above its upper Bollinger Band on September 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BGMS entered a downward trend on September 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 62 of 68 cases where BGMS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on BGMS as a result. In 72 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.
The Moving Average Convergence Divergence (MACD) for BGMS just turned positive on October 13, 2026. Looking at past instances where BGMS's MACD turned positive, the stock continued to rise in 36 of 43 cases over the following month. The odds of a continued upward trend are 84%.
BGMS moved above its 50-day moving average on October 12, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +21.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where BGMS advanced for three days, in 179 of 204 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.836) is normal, around the industry mean (9.236). P/E Ratio (0.203) is within average values for comparable stocks, (38.255). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.212). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (2.410) is also within normal values, averaging (2.201).
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. BGMS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BGMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock worse than average.
The RSI Indicator for MIRM moved out of oversold territory on October 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 14 similar instances when the indicator left oversold territory. In 14 of the 14 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 61 of 67 cases where MIRM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for MIRM just turned positive on October 12, 2026. Looking at past instances where MIRM's MACD turned positive, the stock continued to rise in 37 of 48 cases over the following month. The odds of a continued upward trend are 77%.
Following a +5.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where MIRM advanced for three days, in 235 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
MIRM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on September 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MIRM as a result. In 59 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 61%.
The 50-day moving average for MIRM moved below the 200-day moving average on October 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIRM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Aroon Indicator for MIRM entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is 38 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. MIRM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (26.596) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (8.842) is also within normal values, averaging (437.542).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
BGMS | MIRM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 97 | 64 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 30 Undervalued | 69 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 38 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 56 | 63 | |
P/E GROWTH RATING 1..100 | 1 | 100 | |
SEASONALITY SCORE 1..100 | 90 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BGMS's Valuation (30) in the Biotechnology industry is somewhat better than the same rating for MIRM (69) in the null industry. This means that BGMS’s stock grew somewhat faster than MIRM’s over the last 12 months.
MIRM's Profit vs Risk Rating (38) in the null industry is somewhat better than the same rating for BGMS (100) in the Biotechnology industry. This means that MIRM’s stock grew somewhat faster than BGMS’s over the last 12 months.
MIRM's SMR Rating (100) in the null industry is in the same range as BGMS (100) in the Biotechnology industry. This means that MIRM’s stock grew similarly to BGMS’s over the last 12 months.
BGMS's Price Growth Rating (56) in the Biotechnology industry is in the same range as MIRM (63) in the null industry. This means that BGMS’s stock grew similarly to MIRM’s over the last 12 months.
BGMS's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for MIRM (100) in the null industry. This means that BGMS’s stock grew significantly faster than MIRM’s over the last 12 months.
| BGMS | MIRM | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 89% | 2 days ago 61% |
| MACD ODDS (%) | 2 days ago 84% | 2 days ago 77% |
| TrendWeek ODDS (%) | 2 days ago 85% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 84% | 2 days ago 67% |
| Advances ODDS (%) | 3 days ago 88% | 3 days ago 75% |
| Declines ODDS (%) | 7 days ago 90% | 9 days ago 64% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 57% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BGMS’s FA Score shows that 2 FA rating(s) are green while MIRM’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BGMS’s TA Score shows that 5 TA indicator(s) are bullish while MIRM’s TA Score has 5 bullish TA indicator(s).
BGMS (@Building Products) experienced а +7.50% price change this week, while MIRM (@Biotechnology) price change was +0.47% for the same time period.
The average weekly price growth across all stocks in the @Building Products industry was +0.52%. For the same industry, the average monthly price growth was +3.44%, and the average quarterly price growth was -6.41%.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.22%. For the same industry, the average monthly price growth was -17.98%, and the average quarterly price growth was -18.86%.
BGMS is expected to report earnings on Nov 18, 2026.
MIRM is expected to report earnings on Nov 17, 2026.
The industry manufactures products used in the construction of residential and commercial buildings. The process involves using materials and other products, and processing them to create finished items such as doors, windows, light fittings, floor coverings, climate control products and other building components and home improvement products. Masco Corporation, Allegion PLC and Lennox International Inc. are major manufacturers of such products.
@Biotechnology (-7.22% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NKX | 10.57 | 0.14 | +1.34% |
| Nuveen California AMT-Free Quality Municipal Income Fund | |||
| FMKT | 21.84 | 0.05 | +0.25% |
| The Free Markets ETF | |||
| BSL | 12.97 | 0.02 | +0.15% |
| Blackstone Senior Floating Rate 2027 Term Fund | |||
| NXTE | 47.20 | N/A | N/A |
| AXS Green Alpha ETF (NXTE) | |||
| RSPT | 67.50 | -0.08 | -0.12% |
| Invesco S&P 500 Equal Weight Technology ETF (RSPT) | |||
A.I.dvisor indicates that over the last year, MIRM has been loosely correlated with XERS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MIRM jumps, then XERS could also see price increases.
| Ticker / NAME | Correlation To MIRM | 1D Price Change % | ||
|---|---|---|---|---|
| MIRM | 100% | -7.48% | ||
| XERS - MIRM | 45% Loosely correlated | -2.49% | ||
| KURA - MIRM | 43% Loosely correlated | -5.44% | ||
| EXEL - MIRM | 42% Loosely correlated | -0.52% | ||
| PTCT - MIRM | 41% Loosely correlated | -4.77% | ||
| SLDB - MIRM | 40% Loosely correlated | -13.26% | ||
More | ||||